Overview

Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis

Status:
Enrolling by invitation

Trial end date:
2023-05-31

Target enrollment:
0

Participant gender:
All

Summary

The goal of this clinical trial is to compare the efficacy and safety of Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis in outddor migraine patients attending headache clinic. The main question it aims to answer is whether there is any difference between the efficacy of Topiramate, Amitriptyline monotherapy and combination therapy in migraine prophylaxis. Participants will take Topiramate, Amitriptyline Monotherapy and Combination Therapy and maintain a headache diary. Researchers will compare Topiramate, Amitriptyline Monotherapy and Combination Therapy groups to see if there is any differences in efficacy and safety.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Dr. Reaz Mahmud

Treatments:

Amitriptyline
Topiramate

Criteria

Inclusion Criteria:

1. Diagnosis of migraine (with or without aura) according to the IHS criteria (3rd
edition).

2. Experienced long lasting and frequent (≥2) migraine attacks per month (EFNS
guideline,2009) and impaired quality of life.

3. Age at entry 18-50 years.

4. Willing to participate and give informed written consent.

5. Patients not on other prophylactic medication of migraine.

Exclusion Criteria:

1. Age < 18 years, >50 years

2. Suffering from headaches other than migraine.

3. Patients with serious medical conditions such as Cardiovascular Diseases, Glaucoma,
Liver or Kidney Diseases, Malignancy, BEP.

4. Pregnant, lactating mother.